NCT07227311
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07227311
Title A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.